Table 2.

Cost-effectiveness results of annual HCC surveillance in CHB patients with virological remission

Surveillance age group			compensated cirrhosis					advanced fibrosis (non-cirrhotic)
			Costs per patient ($)	QALYs gained per patient	ICERs vs. no surveillance (US$/QALY)	ICER vs. next screening strategy (US$/QALY)		Costs per patient ($)	QALYs gained per patient	ICERs vs. no surveillance (US$/QALY)	ICER vs. next screening strategy (US$/QALY)
No surveillance			86,161	11.533	/	/		6,011	14.820	/	/
Surveillance (Annual)
	Start age	Stop age
	40	50	88,090	11.609	25,511	25,511		6,490	14.906	5,582	5,582
		55	91,784	11.687	36,475	47,028		9,053	14.981	18,960	34,363
		60	96,631	11.855	32,545	28,928		9,359	15.091	12,347	2,759
		65	102,875	12.018	34,488	38,325		10,495	15.309	9,167	5,213
		70	105,911	12.119	33,742	30,151		11,350	15.405	9,136	8,979
		75	108,207	12.180	34,072	37,196		11,675	15.470	8,720	4,984
	45	55	92,279	11.658	49,181	49,181		9,140	14.940	26,099	26,099
		60	96,977	11.795	41,369	34,279		9,515	15.022	17,330	4,554
		65	102,968	11.963	39,144	35,680		10,535	15.236	10,886	4,780
		70	105,797	12.064	36,990	27,875		11,417	15.337	10,460	8,713
		75	107,985	12.127	36,744	34,674		11,736	15.403	9,822	4,825
	50	60	96,004	11.817	34,726	34,726		9,527	15.030	16,768	16,768
		65	101,448	11.973	34,804	34,947		10,926	15.236	11,824	6,792
		70	104,657	12.078	33,952	30,407		11,988	15.343	11,443	9,959
		75	106,890	12.140	34,192	36,311		12,346	15.405	10,839	5,762
	55	65	95,256	11.817	32,072	32,072		8,288	15.099	8,156	8,156
		70	98,293	11.925	30,969	28,076		9,347	15.197	8,864	10,901
		75	100,639	11.965	33,529	58,543		9,903	15.271	8,635	7,474
	60	70	96,077	11.754	45,022	45,022		8,787	15.044	12,424	12,424
		75	98,005	11.847	37,809	20,731		9,132	15.100	11,171	6,166
	65	75	91,698	11.701	33,100	33,100		8,057	14.951	15,612	15,612

CHB, chronic hepatitis B; HCC, hepatocellular carcinoma; QALY, quality-adjusted life years; ICER, incremental cost-effectiveness ratio